WADA and Peptides

Overview

The World Anti-Doping Agency (WADA) maintains the Prohibited List — an international standard identifying substances and methods prohibited in sport. The list is updated annually and categorized by substance class, with distinctions between substances prohibited at all times, those prohibited in-competition only, and methods of use that are banned regardless of substance.

Peptides appear across multiple categories of the Prohibited List, reflecting the diversity of their biological activities. Growth hormone secretagogues, IGF-1 and its analogs, GLP-1 receptor agonists, and numerous other peptide classes are subject to prohibition. For competitive athletes, understanding which peptides are prohibited — and the detection methods used to identify them — is essential for avoiding inadvertent anti-doping rule violations.

This article covers the current status of peptides on the WADA Prohibited List, the testing methodologies used for detection, and practical implications for athletes subject to anti-doping regulations.

Prohibited Peptide Categories

S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics

This is the primary category under which most prohibited peptides fall. It includes:

Growth Hormone (GH) and its releasing factors:

• Human Growth Hormone (hGH, somatropin)
• Growth Hormone Releasing Hormone (GHRH) and all analogs, including CJC-1295, Sermorelin, Tesamorelin
• Growth Hormone Releasing Peptides (GHRPs), including GHRP-2, GHRP-6, Hexarelin, Ipamorelin
• GH Secretagogue receptor agonists, including MK-677 (Ibutamoren — technically a non-peptide secretagogue but included in this framework)

IGF-1 and related factors:

• IGF-1 (Insulin-like Growth Factor-1) and all isoforms
• IGF-1 LR3 (Long R3 IGF-1)
• Mechano Growth Factor (MGF)
• All IGF-1 binding protein modulators

Erythropoietin (EPO) and related:

• EPO and all erythropoiesis-stimulating agents
• EPO-mimetic peptides (e.g., peginesatide)

Other prohibited peptide hormones:

• ACTH (adrenocorticotropic hormone) and analogs
• Thymosin Beta-4 (TB-500) — explicitly listed
• BPC-157 — status addressed under the catch-all provisions

The Catch-All Clause

WADA's Prohibited List includes provisions that extend prohibition beyond specifically named substances. The S0 category (Non-Approved Substances) states that any pharmacological substance not addressed by subsequent sections of the List and with no current approval for human therapeutic use by any governmental regulatory health authority is prohibited at all times.

This is particularly relevant for peptides like BPC-157, which may not be individually named on the list but fall under this umbrella provision because they are not approved by any regulatory authority for human therapeutic use.

S4: Hormone and Metabolic Modulators

Some peptide-adjacent compounds fall under this category:

• GLP-1 receptor agonists (e.g., Semaglutide) — while primarily metabolic agents, certain uses may be scrutinized
• Insulin — prohibited in-competition and out-of-competition for non-diabetic athletes
• Activin receptor antagonists and myostatin inhibitors (including Follistatin)

Specific Peptide Prohibition Status

Note: The Prohibited List is updated annually. Athletes should always verify current status at the official WADA website or through their sport's anti-doping authority.

Detection Methods

Anti-doping laboratories employ increasingly sophisticated methods to detect peptide use:

Mass Spectrometry-Based Detection

• LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry): The workhorse of peptide detection. Urine and blood samples are processed through liquid chromatography separation followed by tandem mass spectrometry identification. This method can detect intact peptides and their metabolites at very low concentrations
• HRMS (High-Resolution Mass Spectrometry): Provides even greater specificity by measuring molecular mass with high precision, reducing false positives

GH-Specific Testing

Growth hormone detection uses specialized approaches:

• GH isoform test: Detects exogenous recombinant GH by measuring the ratio of different GH isoforms. Recombinant GH is a single isoform (22 kDa), while endogenous GH contains multiple isoforms
• GH biomarker test: Measures IGF-1 and procollagen III peptide (P-III-NP) levels, which increase with GH use. This test has a longer detection window than the isoform test
• Detection of GH secretagogue metabolites: Increasingly, laboratories can detect metabolites of GHRPs and GHRH analogs in urine, providing indirect evidence of secretagogue use

Athlete Biological Passport (ABP)

The ABP is a longitudinal monitoring program that tracks individual athlete biomarkers over time:

• Haematological module: Tracks blood parameters relevant to EPO and blood doping
• Steroidal module: Monitors steroid metabolite ratios
• Endocrine module (emerging): Development of GH and IGF-1 monitoring within the ABP framework is ongoing. Abnormal patterns in GH-related biomarkers over time may indicate peptide use even when specific compounds are not directly detected

Detection Windows

Detection windows vary significantly by compound, dose, route, and analytical method:

Therapeutic Use Exemptions (TUEs)

Athletes with legitimate medical conditions requiring peptide-based treatments can apply for a Therapeutic Use Exemption. The TUE process requires:

1. Documentation of the medical condition by a qualified physician
2. Evidence that the prohibited substance is necessary and that no permitted alternative exists
3. Application through the athlete's national anti-doping organization or international federation
4. Review and approval by a TUE Committee

Common TUE-relevant scenarios involving peptides include insulin for type 1 diabetes and growth hormone for documented growth hormone deficiency.

Practical Implications for Athletes

• Zero tolerance policy: Anti-doping violations carry strict liability — the athlete is responsible regardless of intent or knowledge. Inadvertent use is not a defense against a positive test
• Supplement contamination: Research has documented cases of sports supplements contaminated with peptides or peptide precursors. Athletes should use only third-party tested supplements (e.g., NSF Certified for Sport, Informed Sport)
• Medical disclosure: Athletes must disclose all medications and supplements on doping control forms. Failure to disclose can compound penalties
• Retirement and return: Athletes returning from retirement to competition must be aware that peptides used during retirement may still be detectable and that out-of-competition testing obligations resume
• Support staff responsibility: Coaches, physicians, and other support staff can also face sanctions for involvement in anti-doping rule violations

Disclaimer

This article is for educational and informational purposes only. It does not constitute legal or anti-doping compliance advice. Athletes subject to anti-doping regulations should consult their sport's anti-doping authority and the current WADA Prohibited List for definitive guidance. The Prohibited List is updated annually, and the information in this article may not reflect the most current version.